PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities
Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have significantly enhanced the treatment outcomes in non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. However, the occurrence of acquired resistance to EGFR-TKIs is an unavoidable outcome observed in the...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-04-01
|
| Series: | Pharmacological Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1043661824000677 |
| _version_ | 1797246787731324928 |
|---|---|
| author | Xiaohong Liu Wuxuan Mei Pengfei Zhang Changchun Zeng |
| author_facet | Xiaohong Liu Wuxuan Mei Pengfei Zhang Changchun Zeng |
| author_sort | Xiaohong Liu |
| collection | DOAJ |
| description | Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have significantly enhanced the treatment outcomes in non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. However, the occurrence of acquired resistance to EGFR-TKIs is an unavoidable outcome observed in these patients. Disruption of the PI3K/AKT/mTOR signaling pathway can contribute to the emergence of resistance to EGFR TKIs in lung cancer. The emergence of PIK3CA mutations following treatment with EGFR-TKIs can lead to resistance against EGFR-TKIs. This review provides an overview of the current perspectives regarding the involvement of PI3K/AKT/mTOR signaling in the development of lung cancer. Furthermore, we outline the state-of-the-art therapeutic strategies targeting the PI3K/AKT/mTOR signaling pathway in lung cancer. We highlight the role of PIK3CA mutation as an acquired resistance mechanism against EGFR-TKIs in EGFR-mutant NSCLC. Crucially, we explore therapeutic strategies targeting PIK3CA-mediated resistance to EGFR TKIs in lung cancer, aiming to optimize the effectiveness of treatment. |
| first_indexed | 2024-03-07T14:29:55Z |
| format | Article |
| id | doaj.art-4433642ba76b4aeebe2457254d65adfa |
| institution | Directory Open Access Journal |
| issn | 1096-1186 |
| language | English |
| last_indexed | 2024-04-24T19:48:21Z |
| publishDate | 2024-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Pharmacological Research |
| spelling | doaj.art-4433642ba76b4aeebe2457254d65adfa2024-03-25T04:17:12ZengElsevierPharmacological Research1096-11862024-04-01202107123PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunitiesXiaohong Liu0Wuxuan Mei1Pengfei Zhang2Changchun Zeng3Department of Medical Oncology, Shenzhen Longhua District Central Hospital, Shenzhen 518110, ChinaXianning Medical College, Hubei University of Science and Technology, Xianning 437100, ChinaDepartment of Medical Laboratory, Shenzhen Longhua District Central Hospital, Shenzhen 518110, ChinaDepartment of Medical Laboratory, Shenzhen Longhua District Central Hospital, Shenzhen 518110, China; Corresponding author.Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have significantly enhanced the treatment outcomes in non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. However, the occurrence of acquired resistance to EGFR-TKIs is an unavoidable outcome observed in these patients. Disruption of the PI3K/AKT/mTOR signaling pathway can contribute to the emergence of resistance to EGFR TKIs in lung cancer. The emergence of PIK3CA mutations following treatment with EGFR-TKIs can lead to resistance against EGFR-TKIs. This review provides an overview of the current perspectives regarding the involvement of PI3K/AKT/mTOR signaling in the development of lung cancer. Furthermore, we outline the state-of-the-art therapeutic strategies targeting the PI3K/AKT/mTOR signaling pathway in lung cancer. We highlight the role of PIK3CA mutation as an acquired resistance mechanism against EGFR-TKIs in EGFR-mutant NSCLC. Crucially, we explore therapeutic strategies targeting PIK3CA-mediated resistance to EGFR TKIs in lung cancer, aiming to optimize the effectiveness of treatment.http://www.sciencedirect.com/science/article/pii/S1043661824000677Non-small cell lung cancerEGFRResistancePIK3CACombined therapy |
| spellingShingle | Xiaohong Liu Wuxuan Mei Pengfei Zhang Changchun Zeng PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities Pharmacological Research Non-small cell lung cancer EGFR Resistance PIK3CA Combined therapy |
| title | PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities |
| title_full | PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities |
| title_fullStr | PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities |
| title_full_unstemmed | PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities |
| title_short | PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities |
| title_sort | pik3ca mutation as an acquired resistance driver to egfr tkis in non small cell lung cancer clinical challenges and opportunities |
| topic | Non-small cell lung cancer EGFR Resistance PIK3CA Combined therapy |
| url | http://www.sciencedirect.com/science/article/pii/S1043661824000677 |
| work_keys_str_mv | AT xiaohongliu pik3camutationasanacquiredresistancedrivertoegfrtkisinnonsmallcelllungcancerclinicalchallengesandopportunities AT wuxuanmei pik3camutationasanacquiredresistancedrivertoegfrtkisinnonsmallcelllungcancerclinicalchallengesandopportunities AT pengfeizhang pik3camutationasanacquiredresistancedrivertoegfrtkisinnonsmallcelllungcancerclinicalchallengesandopportunities AT changchunzeng pik3camutationasanacquiredresistancedrivertoegfrtkisinnonsmallcelllungcancerclinicalchallengesandopportunities |